AKAP9 protein, human
Merck Makes Strong Case for Winrevair in Earlier-Stage Pulmonary Arterial Hypertension (PAH) Patients After Positive Phase 3 HYPERION Results
Winrevair; Merck; HYPERION study; PAH; sotatercept; clinical worsening; early disease; activin signaling; FDA approval; Phase 3 trial
Merck Halts HYPERION Trial of Winrevair Early Due to Overwhelming Efficacy in PAH Treatment
Winrevair, sotatercept-csrk, pulmonary arterial hypertension (PAH), HYPERION trial, clinical equipoise, Merck, early trial termination